Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Pharma Seeks Inflation-Liked Price Hikes, Freeze on Patent-Period Cuts for 2027 Revision
Japan’s pharmaceutical industry on August 26 pressed for measures to address mounting business pressures in the FY2027 off-year drug price revision, including NHI price hikes to reflect inflation and a freeze on price cuts for patent-protected medicines. The Federation of…
To read the full story
Related Article
- Generic Re-Pricing Relief Reaches Just 1 in 10 Unprofitable Products: JGA
August 27, 2026
- Chuikyo Kicks Off Debate on FY2027 Off-Year Drug Price Revision
July 9, 2026
- Japan Ministers Agree to Scrap “Spillover” Rule, Plan Wider CEA Price Cuts
December 25, 2025
- Four Ministers Map Out Basic Policy for Drug Pricing Revamp
December 21, 2016
REGULATORY
- Takaichi Puts Health Security on Crisis Management Investment Agenda
October 6, 2026
- Japan Has Limited Drug Pricing Cards to Play on MFN, Should Expand CEA: MOF Official
October 5, 2026
- RMPs to Become Statutory Requirement under PMD Act in May 2027
October 5, 2026
- Japan Panel Calls for Better Infrastructure to Expand RLT Access
October 5, 2026
- Drug Discovery Fund Cleared to Provide Funding to Startups
October 5, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…